explore -WSS

explore

author：hotspot 2025-10-01 22:58:39 - browse：625

When is a billion-dollar deal a bad omen? Has Wall Street gone overboard on Ozempic? And how do you edit a chicken?

We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. We discuss Bristol Myers Squibb’s multibillion-dollar acquisition of Mirati Therapeutics and what it means for a biotech sector still in a slump. We also explain the latest news in the life sciences, including Wall Street’s freakout over GLP-1, CRISPR’ing animals, and the latest in the NASH saga.

For more on what we cover, here’s the news on Mirati; here’s more on biotech venture capital; here’s the latest on Alnylam Pharmaceuticals; here’s more on NASH; here’s the story on xenotransplantation; here’s more on genome-edited chickens; here’s where you can find episodes of Color Code; and here’s where you can subscribe to the First Opinion Podcast.

Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

Previous article： How one medical school became remarkably diverse
Next article： CDC director unscathed in first congressional testimony

WSS

Bernie Sanders gets little from pharma CEOs on drug prices

Pediatric cancer treatments threatened by a new FDA policy

How to pay for weight loss drugs and save Medicare

Resistance to opioid

30 years of 'Listening to Prozac'

Diagnostic tests are hitting their mathematical limits

entertainment

explore

entertainment

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Sick patients collapsed waiting for care at Massachusetts hospital with known safety violations

State Dept. review finds Biden bears some blame for Afghanistan failures

Readout Newsletter: The latest in Pfizer, Moderna, and Sanofi

Supreme Court strikes down use of affirmative action

BIO selects John Crowley as new CEO

Psychedelics group wrestles with new pharma identity

What don’t we know about an Alzheimer’s drug side effect?

Activists slam private health insurers over coverage restrictions

U.K. Biobank has 500,000 peoples' genome sequences available

focus

Sick patients collapsed waiting for care at Massachusetts hospital with known safety violations

Artificial intelligence use in health care faces greater scrutiny in 2024

Will the market for weight loss drugs really reach $100 billion?

Congress must protect the remaining independent doctors

Too many hospitalized Covid

AMAs digital advisors table RPM coding reform proposal, again

hotspot

focus

leisure time

hotspot